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Ak~traet--Reduction a d extrapolation of experimental data concerning both the perturbed and 
unperturbed growth characteristics of a malignant population was the reason for developing a simple 
descriptive mathematical model. 
Data were obtained by inoculating BN/Rij rats i.v. with 107 viable ceils of a transplantable myeiocytic 
leukemia (BNML). At various time points the tumor load in the bone marrow was determined by means 
of a clonogenic stemcell (LCFU-S) assay or by a dose--survival time bioassay (SVL). 
By fitting hypothetical growth curves to the LCFU-S datapoints, using a non-linear least squares 
computer algorithm, an optimal functional relationship between the BNML population size, N, and time 
after inoculation, t, was found. The unperturbed data are best explained by a curve that consists of an 
exponential part which, at a transition point, changes into a Gompertz curve to account for a steady state 
plateau phase. 
Chemotherapy applied for perturbation purposes consisted of a single dose (100 mg/kg) of cyclo- 
phosphamide (CY) given i.p. at day 13. The effect of the drug was modelled as either pulse-shaped or
as a more gradual event. 
In the former case an instantaneous tumor load reduction occurs, after which regrowth can be modelled 
in a way similar to unperturbed growth. Different parameter values apply, resulting in slower population 
size increase and a lower level plateau phase. Statistical significance is rather poor though, owing to 
uncertainty in the observations. 
The tumor load reduction is somewhat larger than can be deduced from dose-response experiments (6.0 
and 5.5 decades, respectively). Correction is possible, without changing the goodness of fit, by introducing 
a time delay in the early exponential phase. 
To model gradual drug influence various functions were tested, i.e. a constant level during some time, 
an exponentially decreasing level, parabolic increase and decrease, and a combination of the first two 
categories. This last one, when superimposed on the function for unperturbed growth, yielded the best 
fit to the observed LCFU-S datapoints. 
Taking the total correlation coefficient, TCC, as measure of goodness of fit (TCC tends to I with 
improving fit) it must be concluded that the instantaneous drug effect model is only slight better than 
the gradual model (TCC=0.85023 and 0.84915, respectively). The SVL datapoints also indicate 
instantaneous rather than gradual drug effect. 
INTRODUCTION 
At present reatment of human acute leukemia often starts successfully with the induction of a 
complete remission by chemotherapy. Initial treatment reduces a typical oad of 10 t2 leukemic ells 
(1 kg) by at least a factor 100, i.e. the possibly remaining 10 g or less cannot be detected by standard 
clinical cytologic methods. The actual number of surviving cells may thus be anything between 0
and 101° . Due to the fact that no information isavailable on the residual tumor load, maintenance 
of the state of complete remission is still a major problem. To try and eradicate residual disease 
either maintenance chemotherapy or high-dose chemotherapy [e.g. cyclophosphamide (CY)] 
combined with total body irradiation (TBI) and bone marrow transplantation (BMT) is applied. 
Failure of these methods, i.e. if not all clonogenic leukemic ells are eliminated, means that sooner 
of later the disease will relapse. 
Therefore, it is of great importance to gain knowledge about the kinetics of growth of the 
leukemic ell population, expecially in the "invisible" area of residual disease. If changes in the 
tumor load, due to both natural (re)growth and under influence of chemotherapy, can be accurately 
quantified, then relapse can be predicted earlier and more effective treatment strategies can be 
designed. 
tThis paper is based on a presentation given at the l l th IMACS Worm Congress, Oslo, Norway, 5-9 Aug., 1985. 
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A way to track down the time course of the size of the leukemic population is by performing 
computer simulation studies, using mathematical models for growth under both unperturbed and 
therapy conditions. Various hypothetical growth curves can be tested for adequate description of 
the data obtained from in vivo experiments. The best fitting curves may be used, by extrapolation 
to the experimentally invisible area, as the most likely description of the growth properties of 
residual disease, as far as they do not contradict any other known physical facts. 
In the past many investigators have employed mathematical models for tumor growth. It is 
generally assumed that a natural human tumor develops from a single transformed cell. Starting 
at time t = 0 with a single cell the growth of a population may be modelled with a linear birth 
process. The population size, N, will increase xponentially with time if a constant probability of 
birth, p, is assumed [1], i.e. N(t)  = exp(p, t). This will still be the case if, more realistically, a death 
process is modelled as well, again with a constant probability [2]. The growth rate will be 
dN/dt = GF-N, where the growth fraction GF is a constant depending on the characteristics of 
the specific tumor investigated (cell cycle time, fraction of resting cells, death rate). 
In practise, experiments starting with a single cell generally will yield some distribution of 
population sizes at time t. At some time after carcinogenesis the tumor may even become xtinct. 
Thus, to some extent umor growth is a stochastic process, requiring stochastic models. Carcino- 
genesis itself may be modelled as a stochastic transformation process as well [3]. 
Also, at some time during their development the majority of tumors appear to deviate from 
growing exponentially. The growth fraction obviously depends on population size. To account for 
this phenomenon many researchers have investigated various growth laws to explain their data, 
e.g. the logistic equation [4] or the Gompertz equation [5]. The appropriateness of these functions 
is based on empirical curve fitting, rather than on any underlying physical or biological arguments. 
Especially when a large range of tumor sizes is involved the Gompertzian law has been demon- 
strated to be the most applicable [4-8]. The growth fraction then decreases with increasing tumor 
size according to GF = A "ln(Nm~x/N), where Nm~x is the maximum population size for t ~ oo, 
and A is either a constant or, if an aspect of randomness in growth must be introduced, A may 
be replaced by a Gaussian white noise process [9]. Effects of heredity, i.e. absolute randomness 
being restricted by the fact that daughter cells behave more like their mother than do their nieces, 
may be taken into account [10]. For similar results with respect o the qualitative aspects tumor 
growth with a size dependent growth fraction may also be modelled by a non-Gompertz equation 
[11]. Again different models take into consideration tumor size dependent birth and death rates 
[12, 13]. 
In the present study the growth characteristics of an acute myelocytic leukemia in the bone 
marrow of the Brown Norway rat, and the influence of chemotherapy, will be evaluated along the 
above indicated lines of curve fitting and simulations. The cell numbers dealt with are relatively 
large. The experimental data are assumed to reveal the development of the mean population size. 
Therefore, no stochastic effects will be considered, but only a population size dependent growth 
fraction. 
MATERIALS AND METHODS 
The rat leukemia model [14] 
The Brown Norway acute myelocytic leukemia (BNML) was induced with 9,10-dimethyl- 
1,2-benzanthracene in a female Brown Norway (BN) rat. Within the BN/Rij rat strain BNML is 
transplantable bycellular transfer. As few as 25 i.v. inoculated BNML cells cause the development 
of leukemia in 50% of the test animals [15]. The principle target organs are liver, spleen and bone 
marrow. The total tumor load at the time of death amounts to 4 x 10 t° cells. The fact that BNML 
behaves very much like human acute myeloid leukemia (AML) explains the relevance of the disease 
for use in experimental tumor treatment s udies. Some major properties are: (a) a slow growth rate; 
(b) the presence of clonogenic leukemic ells; (c) a severe suppression of hemopoiesis owing to an 
absolute decrease in normal hemopoietic stemcells (CFU-S) and (d) a response to chemotherapy 
similar to that of AML. 
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Fig. 1. Inoculated ose vs survival time experiment. The median survival time (MdST) is shown for 
given dose (D). The bars show the range of observed survival times. Log-linear egression yields: 
log(D) = -0.25 x MdST + 12.50, with correlation coefficient r = -0.9962, and 95% confidence limits as 
shown by the shaded area. 
Experiments 
Data concerning the growth pattern of BNML in the BN rat's bone marrow could be derived 
from the following experiments hat had been conducted with 14 wk old male BN/Rij rats. 
(a) A dose-response experiment [16]. Rats were inoculated i.v. with various amounts of BNML 
cells, ranging from 103 to 107 . Time at which death from leukemia occurred was registered. Linear 
regression of log dose and median survival time (MdST), with six rats per datapoint, yielded the 
following relationship (1), which implies that every ten-fold reduction in dose corresponds with 4 
days extra survival time: 
dose = 10 -0.25 × MdST+ 12.50 (1) 
Figure 1 shows the regression line and its 95% confidence limits. 
(b ) Clonogenic leukemic stemcell assays (LCFU-S) [17]. At various times after i.v. inoculation 
with l0 7 BNML cells groups of five rats were sacrificed and the tumor load in the bone marrow 
was determined in the following way. Femoral bone marrow was inoculated i.v. into recipient rats 
that were sacrificed 19 days later. It was experimentally determined--by an assay based on the one 
for normal hemopoietic stemcells [18], as briefly described in the Appendix--that, on average (with 
an accuracy of approx. 10%), one out of every 500 BNML cells present in an inoculum gives rise 
to a spleen colony (seen as a white spot on the spleen surface). Thus, by counting the spleen 
colonies, the total number of BNML cells originally present in the donor rat's marrow can be 
calculated. It is assumed that a femur contains 2.5% of the total bone marrow, and that the BNML 
cells in the bone marrow are homogeneously distributed. 
To check the reproducibility of the results this experiment was repeated several times. Four times 
with and two times without the inclusion of chemotherapy consisting of a single i.v. bolus dose 
of 100 mg/kg CY at day 13. For both cases median survival times were determined as well. 
(c) Dose-survival time bioassay. This experiment resembles the one described under experiment 
(b). The recipient rat is not sacrificed for spleen examination, but its time of death owing to 
leukemia is awaited. Using the dose-response r lationship (1) from experiment (a), the number of 
BNML cells originally present in the donor rat's bone marrow can be calculated from the MdST 
of the recipient rats. 
Data analysis; basic growth curves 
Unperturbed growth. A general equation that expresses the growth of a cell population can be 
written as 
dN/dt = GF(N).N(t) ,  (2) 
in which dN/dt denotes the growth rate, N(t) the population size and GF(N) the growth fraction. 
GF(N) can be regarded as the fraction of the population that doubles its size during time interval 
(t, t + dt), and includes many contributary factors like natural cell loss and tumor environment. 
If the growth fraction as function of the population size is known, then equation (2) can be solved, 
yielding an analytical expression for the development of the population size with the time t. 
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Fig. 2. Basic urves: (a) exponential growth; (b) Gompertz growth and (c) exponential growth with time 
delay. 
Plotting the LCFU-S datapoints on semi-log paper reveals that unperturbed growth is charac- 
terized by an exponential phase (constant population doubling time) followed by a plateau phase 
(constant population size). This growth might be empirically best described by either a contiguous 
exponential and Gompertz curve, or by a Gompertz curve alone [7]. 
In exponential phase GF(N) is a constant, ko, and so is the population doubling time, given 
by t= = ln2/k=. The growth rate is directly proportional to the population size and increases 
exponentially [Fig. 2(a)]. Equation (2) becomes a Gompertz curve if GF(N) decreases exponentially, 
dGF/dt = -A  x GF(N). The larger retardation constant A, the faster the curve reaches a plateau 
level [Fig. 2(b)]. The growth rate first increases to a maximum value, then decreases to zero. 
A state of accellerating rowth can also be simulated by making use of a time delay T: 
GF(N) = k~ x { 1 - exp(-  t/T)}. If T = 0, then GF reduces to ke; if T > 0 and t becomes large, then 
the growth curve will tend to the original exponential curve, but shifted a distance T forwards in 
time [Fig. 2(c)]. 
Perturbed growth. The influence of chemotherapy can be modelled by subtracting a growth 
inhibition term, D(N, t), from equation (2). This term can be regarded as the cell quantity removed 
from the population during time increment dt. It depends on the therapy regimen and the tumor 
sensitivity, and includes environmental changes and augmented cell loss caused by the drug. If D 
is large enough the growth rate becomes negative and the tumor regresses. It was found for 
laboratory cell lines growing exponentially that a certain drug level kills a fixed percentage of the 
population. In clinical practice, where Gompertzian tumor growth is rather common, medium size 
tumors often are the most sensitive for chemotherapy. A hypothetical expression for D which is 
in accordance with these findings was derived by Norton and Simon [19]. In a multiplicative way 
D is proportional to the level of therapy, L(t), which comprises drug dose, route of administration, 
bioavailability and other pharmacokinetic factors; to the population size; and to the (unperturbed) 
growth fraction. Thus, 
dN /dt = GF(N). N(t) - K. L (t). GF(N). N(t). (3) 
In exponential phase GF is a constant, so, for given level L(t), growth inhibition in equation (3) 
becomes proportional to N(t). In Gompertzian growth the relative effect of some given L is 
maximal for intermediate N, for GF × N then is largest. Therefore, equation (3) is potentially in 
accordance with clinical experience. 
Several assumptions can be made concerning the shape of the function L(t). Rapid adminis- 
tration combined with a short plasma half-time (20' [20]) of CY allows an instantaneous drug effect 
model, in which L(t) is pulse-shaped. On the other hand CY must first be metabolized by liver 
microsomes to become an active (alkylating) compound. Secondly, prolonged presence of CY in 
the bone marrow has been demonstrated (e.g., 14% of the given dose still after 12h [21]). 
Furthermore, cells show an enhanced rate of death for some 3 days after a 3 h exposure to CY 
[22]. So, longer lasting drug influence models hould also be considered. For instance, the therapy 
level might remain constant for some time. In view of the nature of drug distribution processes 
in general (diffusion and possibly saturation effects) an exponentially decreasing L(t) is another 
obvious choice. Also, a combination might be adequate. Finally, the course of the drug level might 
also be well described with a parabolic increase and decrease. The model equations are, for 
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Fig. 3. Hypothetical functions to describe therapy level. 
subsequent modes 
K.L( t )=H'3( t t ) ,  for t - -  tt, ] 
t 
K.L ( t )=H,  for t,< =t< =tf, 
K .L ( t )= H.exp( -k l . ( t -  t,)), for t > = t,  
K.L(t )  = k2 .H .exp( -k l  .(t - t,))/{k3 + H.exp( -k l . ( t  - it))}, for t > = tt, 
K.L ( t )=H.{( t , - t f )2 - ( t - t f )2} ,  for t,< =t< =2t / - t t ,  
(4) 
where t, is time of drug administration, 6(tt) is the unit pulse and H, tf, k 1, k2 and k3 are positive 
constants (model parameters). Outside the given time intervals K.L ( t )= 0. The functions are 
shown in Fig. 3. 
Data analysis; model evaluation 
Curve fitting. For unperturbed growth the model equation (2) was solved analytically, using the 
basic exponential and contiguous Gompertz curves. The time course of the population size then 
is given by 
N(t) = Ng.exp{ln2.(t - Q)/t=}, for 0 < = t < = tg, 
N(t) = Nt.exp{-ln2.[1 - exp(-A "(t - Q))]/(A .t=)}, for t > Q. (5) 
The model parameters are the doubling time in exponential phase, t,, the transition point: 
time tg and population size Ng, and the retardation constant A. If only Gompertzian growth is 
concerned, then t~ = 0. To find the optimum parameter values (considered as elements of the vector 
p) the curves (5) were fitted to the M observed atapoints Nob~(ti) using a non-linear least squares 
method. The computer algorithms for either a gradient or a grid search, starting from some initial 
estimate, were derived from Ref. [23]. In minimizing the error function 
E =~W~'{Nobs-N.,c(p)} 2, i= 1, M, (6) 
three weighting options were available: W -- 1 (normal); W -- l/Nobs(tl) (statistical weight, favoring 
smaller over larger observed values); W = 1/Sdab ~(t~) (instrumental weight, putting emphasis on the 
more accurate data by looking at the observed standard eviations). For the separate optimization 
runs each option was evaluated and the one yielding the best fit was maintained. 
To simulate chemotherapy the optimum parameter values for unperturbed growth were 
substituted in equation (3). Additional parameter values related to each particular mode of drug 
action, equation (4), were estimated by fitting curve 
N(t + At) = N(t) + At. (dN/dt), (7) 
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to observed atapoints [where At = 0.1 and dN/dt is given by equation (3)], using the same least 
squares routines. 
Goodness of fit. The growth curve that results in the best fit of the observed ata is the best 
model-- if  it does not contradict any known physical facts. As a criterion for the fit the residual 
sum of squares can be used 
SSR = ~{dev2/var},, i=  1, M, (8 )  
dev, = {Nobs -- Ncatc(P)}, (9) 
={ [= var = dev i -  dev#M M - 1). 
where 
(10) 
Low SSR values mean better fits. Also, especially to compare the fit of several curves to a same 
set of observations, the total correlation coefficient is a useful measure. As it is defined as 
I ) 112 
TCC= l -2dev~/EN2o~ , (11) 
the closer to 1, the better the fit. 
Computation. All programs were written in FORTRAN 5 and used on a DATA GENERAL 
Eclipse MV/10000 minicomputer. 
Test data. To test the least squares optimization routines' performance with respect o the 
reliability of the resulting parameter values two sets of test data were created. Twelve points, 
equidistant in the range 3-25 d, and seven non-equidistant points, were calculated from equation 
(5), using tc = 0.75, tg = 8.5, Ng = 0.2 × 109 and A = 0.45. Reconstruction f the original curve from 
these sets was attempted, starting with initial parameter estimates both 10% above and below true 
values. Good fits were obtained (TCC > 0.9999). Some starting point dependency was observed. 
Parameter uncertainty (the estimated standard eviations can be rather large) decreases slightly 
with increasing number of observations. The optimum estimates for t, and t s as returned by the 
routines tend to their true values, larger relative deviations occur in Ng (10%) and, to lesser extent, 
in A (5%), 
RESULTS AND DISCUSSION 
The observations pertaining to a single set of LCFU-S experiments were taken first to find the 
best descriptive model for unperturbed growth. Next, using this model, the various functions 
describing drug influence were evaluated. The resulting best fitting models for growth and regrowth 
were subsequently examined with respect o the datapoints from all LCFU-S experiments aken 
together. The results are presented below. 
Single dataset 
Unperturbed growth of BNML in bone marrow. The datapoints were fitted with an exponential 
and contiguous Gompertz curve (EG), and a Gompertz curve alone (G). The results are shown 
in Fig. 4, curves A and B, respectively. The EG curve yields the best fit in terms of TCC and SSR. 
The population starts with 1.3 x 105 cells (1.3% of inoculum) and at time of death (day 22) has 
grown to 7.3 x 109 (18.3% of overall BNML burden at death). The G curve starts with very few 
cells (0.03% of dose), and, though this model also fits the data, a main (biological) argument that 
can be raised against its validity is that the initial population doubling time amounts to 7.2 h, 
whereas the cell cycle time is almost twice as large (14 h according to previous autoradiography 
experiments). Being too fast in early phase, this model is not further considered. 
Perturbed growth; instantaneous drug influence model. First two simulations were performed, 
based on the assumption that after instantaneous size reduction the population will regrow in a 
way identical to the unperturbed pattern. 
Owing to CY treatment at day 13 the rats' life is prolonged by 22 days (MdST = 44 instead of 
22). According to the experimentally established ose response [equation (1)], i.e. every 4d  
increased lifespan means a factor 10 reduction in cell number, this should correspond to a tumor 
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Fig. 4. Fitted growth curves and datapoints (with standard deviations) from a single series of LCFU-S 
experiments; instantaneous CY influence model. 
Unperturbed growth: 
A- -EG,  TCC = 0.98895, SS R = 4.00, tg = 8.20 _+ 1.88 d, Ns = 1.24 × 108 + 1.25 × 10 s, 
t ,=0.83  +0.31 d, A =0.19-t-0.23 ( l /d);  
B---G, TCC = 0.98480, SSR = 4.70, t~ = 0.0 d, Ng = 3.07 × 103+ 3.03 × I03, 
t, = 0.30 _+ 0.03 d, A = 0.15 4- 0.02 ( l /d);  
CY treated: 
C---TCC = 0.00000, SS R = 5.30, 5.5 LCK, regrowth as A; 
D---TCC = 0.00000, SS R = 5.30, 7.4 LCK (correction for MdST), regrowth as A; 
F,---EG, TCC = 0.98367, SSR = 4.06, 7.36 LCK, t~ = 24.85 + 1.27 d, N t = 1.45 x 107 _ 1.37 x 107, 
te = 0.67 _ 0.32 d, A = 0.34 4- 0.21 ( l /d);  
F TCC = 0.98367, SS R = 4.05, as E, time delay T = 4.5 d to correct for 5.5 LCK. 
load reduction of 5.5 decades (=22/4), or 5.5 log cell kill (LCK). In other words, at day 13 the 
tumor load drops from 1.7 x 109 to 8.5 X 103. Subsequent regrowth identical to growth (curve C, 
Fig. 5) results in an expected MdST = 38.8. 
To match expected and observed MdST a second simulation shifts the growth curve D to the 
right. This, however, necessitates 7.4 LCK, which is rather large. Furthermore, neither simulation 
fits the observed atapoints. 
Abandoning the "regrowth equals growth" hypothesis an EG curve fitted to the data (E, Fig. 4) 
proves much better although 7.4 LCK is found here too. By allowing a time delay T = 4.5 d in 
early exponential phase this value can be reset to 5.5 (curve F), without improving the goodness 
of fit. In this model regrowth after chemotherapy is faster than unperturbed growth, the plateau 
phase is reached sooner and death occurs at a lower number of BNML cells. 
Perturbed growth; gradual drug influence model. The hypothetical functions that describe gradual 
drug influence (Fig. 3, modes 2-5) were tested by fitting them to the observed atapoints, using 
the unperturbed EG curve as basis. For each mode the best fits are shown in Fig. 5, in sequence 
curves G, H, I, J. Mode 2, constant therapy level for some time, is the least satisfactory. The other 
modes do not differ very much in goodness of fit. The TCC and SSR criteria appear to be not quite 
unanimous. 
For intermediate cell numbers all curves lie rather to the right of the observations. Also, the 
predicted MdST lies beyond the observed value, unless death occurs at a somewhat lower tumor 
load after treatment han after unperturbed growth. By modifying the growth equation (3) 
improvement (left shift) can be achieved: gradual drug influence is modelled with therapy level, 
K. L(t), according to mode 4, but the GF factor is omitted in the second righthand term and it 
is made a function of N times a positive constant F, F > 1, in the first term on the right: 
dN(t)/dt = GF(F. N). N(t) - K. L (t). N(t). (12) 
C.A.M.W.A. 14/9-12--H 
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Fig. 5. F itted growth curves and datapoints  (with standard deviat ions) from a single series of  LCFU-S  
experiments; gradual  CY  influence models. 
Unperturbed growth: 
A---see Fig. 4; 
CY treated: 
Cr- -TCC = 0.95844, SS R = 6.53, K.L( t )  = 5.74 13 < t < 16.7, AUC = 21.2; 
H - -TCC = 0.99335, SSR = 6.34, K.L(T)  = 8.58exp( -0 .4 ( t  - 13)), AUC = 21.4; 
I - -TCC = 0.99333, SS R = 6.57, K.L ( t )= 8.61 x 15exp( -1 .2 ( t -  13))/{I + 15exp( -1 .2 ( t -  13))}, 
AUC = 19.9; 
J - -TCC = 0.99327, SS R = 6.12, K .L(t) = 8{(13 - 14.2) 2 - (t - 14.2)2}, AUC = 16.1; 
K - -TCC = 0.99733, SS R = 4.90, equat ion (12), F = 10.02, max 5.8 LCK at day 16.5, 
K.L( t )  = 5.12 x 86 .01exp( -  1.6(t - 13))/{1.5 + 86 .01exp( -  1.6(t - 13))}, AUC = 13.0. 
Thus, by the former modification, a given therapy level L(t) causes cell loss proportional to the 
population size N(t) (constant percentage kill). The biological meaning of the latter modification 
is not yet clear: after therapy the GF at a certain population size equals the GF of an F times larger 
unperturbed population. In other words, therapy makes the transition to Gompertzian growth 
occur sooner, and the plateau phase level lower. Curve K in Fig. 5 shows the best fit of the last 
model to the datapoints. 
All LCFU-S datasets combined 
The procedure as described above was repeated with all datapoints acquired from several similar 
experiments, whose purpose was the confirmation of the slope of the growth curve in exponential 
phase and of the level of the plateau phase. The different datasets (Fig. 6) show some shift along 
the time axis, probably owing to variance in the inoculation circumstances. As tumor load 
development in the spleen and bone marrow likely correlate independent on inoculum, using spleen 
weight as reference in future experiments, rather than absolute time, may result in better 
reproducibility. 
In exponential phase the EG curve that fits the joined unperturbed data best (Fig. 6, curve L) 
does not differ much in slope, nor in predicted ay zero population size, from the best single dataset 
fit. A difference xists in the plateau phases, which now attains a lower level with 1.3 x 109 BNML 
cells in the marrow at death (3% of total burden). 
Chemotherapy again is modelled as an instantaneous or a gradual event. In the former case, by 
fitting an EG curve to the perturbed atapoints, 6.0 LCK results at day 13. Introducing time delay 
T = 1.72 days in initial exponential phase allows the size reduction to stop at a 5.5 LCK value. 
Once again without effect on the goodness of fit (Fig. 6, curves M and N). 
The necessity for the time delay is not immediately apparent from the shown data. The 5.5 value 
is based on the observed elay in MdST after therapy and thus concerns what happens on average 
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in the total animal. It might be possible that the drug effect is larger in the bone marrow, and 
accordingly smaller in, say, the liver (an organ that by nature better copes with toxic compounds). 
On the other hand preliminary data from running experiments with both chemo- and radiotherapy 
combined indicate that the LCK cannot be this large, otherwise many more "cures" should have 
been seen. 
In contrast to the single dataset case regrowth after therapy here appears to be slower 
(te=O.97d) than unperturbed growth (to=0.78d). Though the standard deviations of the 
observations are rather large, the difference in doubling time therefore not very significant, this 
phenomenon would agree with the reported greater CY sensitivity of rapidly proliferating cells [24]. 
It would imply that the BNML cells are heterogeneous with respect to cell cycle time, faster cycling 
cells being preferably killed. This hypothesis may be tested by reinoculating rats with BNML cells 
that have survived CY treatment, and see whether the growth kinetics differ from the growth 
pattern of non-treated cells. If not, another hypothesis that cellular growth properties themselves 
remain constant, but greater cell loss occurs in the treated rat owing to the fact that some natural 
defence mechanism (immunology?) has had time to develop. CY Influence on the tumor 
environment may also play some role. 
To model gradual drug influence mode 4 therapy level was chosen in combination with the 
modified growth equation (12). The resulting curve (Fig. 6, O) fits the data only slightly poorer 
than the instantaneous model (curve N). The difference in goodness of fit is even smaller for the 
whole curves (fit to both perturbed and unperturbed data). 
The dose-survival bioassay data 
The dose-survival bioassay experiments were conducted to yield more information on the 
residual tumor load just after therapy. As the method is able to detect BNML cells at lower 
frequencies compared with the LCFU-S procedure a convincing justification for introducing a time 
lolo tl t 2 
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Fig. 6. Fitted growth curves and datapoints (with their standard eviations) from all series of LCFU-S 
experiments: Q- -LCFU-S  assay, not treated; O- -LCFU-S  assay, treated; A- -dose-surv iva l  bioassay. 
Unperturbed growth: 
L - -EG,  TCC = 0.88075, SSR = 22.1, t s = 8.60 + 3.35 d, Nf = 1.82 x l0 s _+ 3.76 x l0 s, 
t e = 0.78 + 0.40 d, A = 0.44 4- 0.30 (l/d); 
CY treated, instantaneous model: 
M--EG,  TCC = 0.85023 (overall = 0.88030), SSR = 7.82 (overall = 29.8), 6.03 LCK, t t = 27.40 _+ 5.90 d, 
Ng = 2.70 x 107 + 5.90 x 107, t, = 0.97 + 0.53 d, A = 0.23 + 0.54 ( l /d);  
N - -TCC ffi 0.85023 (0.88030), SSR = 7.82 (21.4), as M, time delay T = 1.7d to correct for 5.5 LCK; 
CY treated, gradual model: 
O--TCC = 0.84915 (0.88028), SSR = 7.99 (21.4), equation (12), F = 4.39, 
K.L(t) = 4.78 x 86.02exp(-1.6(t  - 13))/{1.5 + 86.02exp(-1.6(t  - 13))}, AUC = 12.2. 
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delay might be found. However, the results, also plotted in Fig. 6, indicate a very steep descent 
of the growth curve, suggesting an instantaneous rather than gradual chemotherapy effect. The 
reduction in population size is high (7 LCK) and, in contrast with the LCFU-S data, subsequent 
regrowth is very fast. Too fast in fact to be explained by proliferation of the surviving BNML cells 
alone; the population doubling time of 12 h is less than the cell cycle time (14 h). Besides, it 
disagrees with the expected CY effects of enhanced death and greater kill of cells with short cycle 
times. An explanation might be a BNML cell repopulation by migration from other organs like 
liver and spleen. Therefore, the BNML growth kinetics in those organs must be examined first. 
In conclusion it can be said that unperturbed growth of the BNML population in the BN rat 
bone marrow, initiated by i.v. inoculation of BNML cells, is characterized by an exponential phase 
followed by a Gompertzian phase. The effect of a single high dose of CY is an instantaneous 
reduction in population size of some 6 decades, after which a similar regrowth pattern follows. The 
necessity of introducing a time delay during initial residual disease, or just the opposite, i.e. 
modelling cell import from elsewhere, has not yet clearly been demonstrated. An explanation for 
the discrepancy between the LCFU-S and bioassay data must still be found as well. 
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APPENDIX  
Experimental Determination of the f-Factor, Relating the Number of Spleen Colonies Counted to the Number of Leukemic 
Cells Injected 
Let a cell suspension consist of C cells, among which is an unknown amount, L, of leukemic ells with the capability 
to form colonies in the spleen (LCFU-S). A fraction k. C cells is injected into a recipient rat. Upon examination of the 
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spleen 19 days later, let the number of spleen colonies counted be p. These colonies are due to p LCFU-S out of the k .L 
inoculated ones (contained in the k. C cells inoculated) having reached the spleen. The dilution factor f i s  the ratio p/(k. L). 
The remaining fraction (1  - k). C, containing (1 - k). L LCFU-S, are injected into another ecipient rat. After a certain 
time its spleen is taken out and a cell suspension is made. This suspension must contain f .  (1 -k ) ' L  LCFU-S, i.e. the 
f-factor--assumed to be a constant--times the number of LCFU-S inoculated. 
The suspension is injected into a secondary recipient. The spleen of this recipient hen should contain f.f.(1 -k ) .  L 
LCFU-S, or spleen colonies, 19 days later. Let the number of colonies counted by q. Now, two equations are available, 
f . f .  (I - k). L = q andf .  k.  L = p, from which the two unknown variables, land  L, can be found, e.g. , f  = k .q/((l - k).p). 
